Amsel Medical Corporation news
Amsel Medical Corp. today announced the expansion of its medical advisory team as the company advances the current product commercialization phase to address the demand for minimally invasive, simple and secure occlusion.
Joining the advisory team are -
- Col. John Dorsch, DO, USAF, Retired; prior wing surgeon, physician, and medical officer for the 24th Special Operations Wing (Air Force Special Operations Command) and Air Force Pararescue Medical Director
- Josh
Amsel Medical Corporation today announced receipt of award and signing of a contract for a non-dilutive AFWERX Tactical Funding Increase (TACFI) of $1.5 million augmenting its original $1M Phase II SBIR Grant.
This effort is sponsored by the Air Force Research Laboratory and will enable Amsel Medical to bridge its Phase II efforts towards Phase III commercial scaling. It facilitates the delivery of strategic capabilities to the U.S. Air Force, Special Operations Co
The good news for his patient was that she was young. A lower extremity bypass procedure - like any surgery - can be more difficult as we age.
The bad news was that the best veins for the procedure - which involves grafting a vein from another part of the body to bypass her blocked arteries in the leg - were unusable. The patient had undergone varicose vein treatments as a young woman that had destroyed her leg veins, the best options for the bypass procedure.
Why
Amsel Medical Corp. today announced the appointment of Lowell S. Kabnick as a consultant acting as Director of Clinical and Medical Affairs, as the company advances the current product commercialization phase to address the demand for minimally invasive, simple and secure occlusion.
In addition to serving as the Chancellor of the Vein & Lymphatic University, Dr. Kabnick is the previous Director of Medical Operations for United Vein Centers. Prior to that, he served in t
Amsel Medical Corp. today announced the appointment of Jeff Willis as Senior Director of Engineering to help drive the current product commercialization phase and implement the company’s strategy to address the demand for minimally invasive, simple and secure occlusion.
“Jeff is an exceptionally focused engineer and executor,” said Amsel Medical CEO David Doster. “He brings a consistent reputation for delivering quality products that serve market needs and are
Amsel Medical Corp. today announced the appointment of Robert M. Rossell as Chief Commercial Officer to drive the current commercial phase and implement the company’s strategy to address the demand for minimally invasive, simple and secure occlusion.
“I’ve worked with Rob over many years. He brings a great depth of experience, commercial expertise and a track record of success.” said Amsel Medical CEO David Doster. “Under Rob’s commercial leadership
Amsel Medical said today that it won FDA 510(k) clearance for its Amsel Endo Occluder device intended for occluding blood vessels during endoscopic procedures.
The Cambridge, Mass.-based company touted that the clearance is the third the company has received from the FDA so far for its portfolio of occluder devices.
The Amsel Endo Occluder is a mechanical occlusion clip delivered through a fine needle inten
- Amsel Medical Corporation Announces Industry Exhibit of the Amsel Occluder Device at the 2017 Veith Symposium (NY) November 14-18, 2017.
- The Amsel Occluder Device is intended for use in open general surgery procedures on tubular structures or vessels wherever a metal ligating clip is indicated and within the size range of 2.0mm to 7.0mm diameter.